Sterile eye drops fail differently than most over-the-counter drugs. If a tablet has a labeling error, you may catch it before swallowing it. If an ophthalmic product has a sterility problem, the first warning can be pain, discharge, blurred vision, or an emergency eye visit. That is why the AvKARE eye drops recall deserves a hard look from anyone planning to buy lubricating drops, re-order a bottle, or keep backup eye drops in a medicine cabinet.
RecallTracker now tracks {{RECALL_COUNT}} recalls across {{AGENCY_COUNT}} agencies, including FDA drug recalls and cross-border safety notices. AvKARE is only one company in that larger system, but its ophthalmic recall is a good example of how consumers get exposed: a private-label eye drop looks routine, the package is familiar, the active ingredients are common, and the real issue sits upstream in manufacturing controls the buyer never sees.
As of April 12, 2026, AvKARE's recall page still showed a 2025 ophthalmic recall notice covering multiple eye-drop products. The company told customers to discontinue use of affected lots and remove them from active inventory. FDA later published a warning letter to BRS Analytical Services, the contract manufacturer connected to the recall, describing serious current good manufacturing practice problems and a voluntary April 23, 2025 recall of distributed drug products due to CGMP deviations and lack of assurance of sterility.
If you are trying to decide whether to buy AvKARE eye drops, whether a bottle in your home is safe to use, or whether a pharmacy-supplied product should be returned, the right move is not guessing from brand reputation. The right move is verifying the exact product, the lot, and the recall status. You can search the recall database if you have a product name, or use a barcode scanner when the bottle or carton is in front of you.
The current AvKARE recall notice groups five ophthalmic products under its 2025 recall listing. These are not all the same formulation, and that matters because many consumers remember only a generic description like "artificial tears" or "lubricant drops." For recall checking, the exact product name and NDC are more reliable than memory.
| AvKARE product on recall notice | NDC | Product type | Why it matters |
|---|---|---|---|
| Artificial Tears Ophthalmic Solution | 50268-043-15 | Lubricating eye drops | Common dry-eye purchase; easy to confuse with non-recalled store-brand tears |
| Carboxymethylcellulose Sodium Ophthalmic Gel 1% | 50268-066-15 | Gel drops | Thicker formula often used for more persistent dryness |
| Carboxymethylcellulose Sodium Ophthalmic Solution | 50268-068-15 | Lubricating solution | Similar naming to many private-label eye products |
| Lubricant Eye Drops Solution | 50268-126-15 | Lubricating drops | Generic label language can make home identification harder |
| Polyvinyl Alcohol Ophthalmic Solution | 50268-678-15 | Lubricating drops | Another common dry-eye ingredient category |
AvKARE's notice is important for two reasons. First, the affected list spans several formulations, which means a shopper cannot assume only one niche SKU was involved. Second, the products were sold under straightforward generic-style names that overlap with how many pharmacies and discount retailers describe eye drops. That creates confusion at the exact moment a consumer needs precision.
This is also why simple product-category searches are not enough. Searching "artificial tears recall" may show you the well-known EzriCare or Delsam events from 2023, but it may not tell you whether your specific AvKARE-labeled bottle is affected. If you want broader context on how drug recalls are handled after a defect is found, our drug recall guide breaks down the process from notice to consumer action.
One practical detail from AvKARE's recall materials stands out: the products were first shipped between May 26, 2023 and April 21, 2025. That does not mean every bottle sold in that window is recalled. It means the affected lots were in distribution long enough that a bottle purchased months earlier could still be sitting in a bathroom drawer, a first-aid kit, or a clinic supply cabinet.
The public-facing recall language from AvKARE points to manufacturing CGMP deviations identified during an FDA audit. That wording is easy to read past, but consumers should not treat it as vague legal boilerplate. In sterile eye products, CGMP failures are not cosmetic paperwork problems. They go directly to whether the manufacturer could reliably keep the product sterile and consistent.
FDA's September 17, 2025 warning letter to BRS Analytical Services gives the sharper picture. The agency described major aseptic-processing failures, including gaps between the ISO 5 aseptic area and the surrounding warehouse, inadequate pressure differentials, deficient environmental monitoring, poor operator practices in critical areas, weak media-fill simulations, and inadequate sterilization validation. FDA also said the firm distributed sterile over-the-counter drug products manufactured under unacceptable conditions and noted that on April 23, 2025 the company issued a voluntary recall of distributed products because of CGMP deviations and lack of assurance of sterility.
For a consumer, "lack of assurance of sterility" is the phrase that matters most. Eye drops are intended to bypass some of the body's normal defenses. FDA has repeatedly warned that contaminated ophthalmic products can lead to serious eye infections, and in other eye-drop events the agency has tied contamination to hospitalization, permanent vision loss, and death. That does not mean every recalled AvKARE bottle caused injuries. It means the risk profile is high enough that once sterility can no longer be trusted, the safe instruction is to stop using the product.
There is also a difference between a known contamination event and a sterility-assurance failure. A recall may happen because bacteria or fungi were found in product or in testing. It may also happen because the manufacturing process was so compromised that no one can credibly say the released lots were sterile. The second category often sounds less dramatic in a recall notice, but from a buyer's standpoint it is not a reason to be casual. If a firm cannot support sterility assurance, you should behave as though the product cannot be trusted in your eye.
That broader lesson is bigger than one brand. FDA's 2023 and 2024 warnings about multiple over-the-counter eye-drop products showed the same pattern: store-shelf familiarity did not protect consumers from sterile manufacturing failures. A bottle can look ordinary and still sit inside a serious quality problem.
This is the part where people make preventable mistakes. They search the internet, see a screenshot, compare bottle color, and assume they are clear. That is not enough. Eye-drop recalls are often lot-specific. Packaging can change. Multiple products can share similar names. The safer process is mechanical and boring, which is exactly what you want.
Use this checklist:
The most common failure point is that consumers look only at the front label. Many ophthalmic bottles look interchangeable from the front panel. The useful identifiers are usually on the side panel, box flap, crimp, or printed bottle text. If your bottle came from a pharmacy, check the receipt bag or prescription paperwork too. Private-label drug distribution can make the front-facing brand less informative than the backend product code.
Another failure point is assuming an unopened bottle is automatically fine. It is not. Sterility risk does not disappear because the consumer has not yet broken the seal. If the lot is recalled, the fact that it is unopened is a reason not to use it, not a reason to save it for later.
If you are buying replacement drops and want to avoid guesswork, do not rely on memory of what was recalled last year. Search fresh. A shopper standing in an aisle can search the recall database by product name in seconds before checking out. That is faster than dealing with a return, and much faster than dealing with an avoidable eye problem.
The right threshold for concern is lower with eye products than with many other consumer drugs. A mild headache after one dose of an oral medication might be monitored at home. New eye pain after using a recalled ophthalmic product deserves more respect.
Symptoms that justify prompt medical advice include:
Symptoms that justify urgent or same-day evaluation include severe pain, rapidly worsening redness, major vision change, or signs that only one eye became acutely worse soon after exposure. If a clinician examines you, bring the bottle or a photo of the label and lot code. "I used some artificial tears" is not enough history. "I used AvKARE Artificial Tears Ophthalmic Solution, NDC 50268-043-15, from a recalled lot" is clinically useful.
Consumers also need to separate expected minor effects from red flags. Many lubricating eye drops can briefly blur vision or sting for a moment. That does not automatically signal an emergency. The concern rises when symptoms are persistent, intensify, or fit an infection picture. When sterility is in question, it is better to get dismissed for over-caution than to wait through a worsening corneal infection.
FDA's prior public warnings on other contaminated eye drops make this point concrete. In the EzriCare and Delsam artificial tears event, the agency linked use to infections that included hospitalization, permanent vision loss, and one death with bloodstream infection. That outbreak involved different products and a different company, but it is the clearest reminder of why consumers should take ophthalmic recalls seriously instead of treating them like routine packaging corrections.
This is the transactional question behind most searches. People rarely search a brand plus a product category because they want a recall history lesson. They want to know whether they should spend money on it, return it, or move to a substitute.
A hard rule works well here: do not buy or keep using any AvKARE ophthalmic product unless you can verify the exact item is not part of the recall and is not from an affected lot. Verification matters more than opinion. A brand may continue selling other products. A retailer may still have older inventory in the channel. A marketplace listing may have stale photos. None of that answers the only question that counts, which is whether the exact bottle in front of you is clear.
There are three buyer scenarios:
Do not use it until you verify the product and lot. If it matches a recalled product and affected lot, stop. If you cannot verify it because the label is damaged or the lot is unreadable, the conservative move is replacement, not use.
Check the listing details, product photos, and seller information before purchase, then verify again when the bottle arrives. Online marketplace inventory can be especially messy because third-party sellers may hold old stock longer than large chain pharmacies.
Treat inventory review as a batch process. Pull every bottle, sort by product name and NDC, isolate anything matching the recall notice, and document what was removed. Shared medicine cabinets are where recalled products linger.
A recall does not automatically mean a brand is permanently unusable, but it does raise the standard you should apply before buying again. If you want to compare another eye-drop brand's recall history before switching, our Ivizia eye drops safety post shows how to evaluate recall language, sterility concerns, and consumer action steps in another ophthalmic category.
Once you confirm a recalled product, the next steps should be fast and practical. Do not overcomplicate it.
AvKARE's recall page tells customers to examine inventory, discontinue use of listed lots, and remove them from active inventory. The company also says it will issue full credit including shipping cost for returns. That is useful if you are managing clinic stock, but home users should care more about quick isolation than about return logistics. First make sure no one uses the bottle again. Then deal with refund or credit.
If you bought the product from a pharmacy, ask a direct question: "Was my dispensed bottle from a recalled lot?" Pharmacies can sometimes answer more precisely than a consumer can because they may have purchase and dispensing records. If you bought it over the counter, your evidence is usually the bottle, the box, and your receipt history.
One more practical point: do not transfer the remaining drops into another container, do not keep them "just in case," and do not give them to someone else because they seem unopened. Recalled sterile eye products should move toward isolation and exit, not reuse.
Consumers often assume eye-drop recalls are one-off brand problems. The record is broader than that. FDA's public warnings in 2023 and 2024 covered multiple ophthalmic products from several brands and retailers because of insanitary conditions, positive bacterial findings, contamination risk, or other sterile-manufacturing failures. That pattern matters because it changes how you should shop.
Dry-eye and lubricant drops are easy to treat like commodity products. Many are inexpensive, look nearly identical, and use familiar active ingredients such as carboxymethylcellulose, polyethylene glycol, propylene glycol, or polyvinyl alcohol. But sterile manufacturing quality is not visible from the shelf. Two products can look interchangeable and have very different production histories.
That is why RecallTracker's value is not limited to emergency recalls. The database helps buyers make basic screening decisions before use. If a household relies on lubricant drops, allergy drops, contact-lens rewetting drops, or pediatric eye products, routine verification is rational, not paranoid. Across {{AGENCY_COUNT}} agencies and {{COUNTRY_COUNT}} countries, the underlying lesson is the same: sterile products deserve active checking because recall risk is not obvious from packaging.
For parents, caregivers, and people with chronic dry eye, the exposure risk is even higher because the same product may be used repeatedly over weeks. Repeated exposure to a problem bottle creates more chances for harm than a single one-off use. That is another reason to remove uncertainty early instead of waiting for symptoms.
The best recall workflow is the one you will actually use when you are tired, busy, and standing under bad bathroom lighting trying to read a tiny lot code. That is where speed matters.
RecallTracker helps in three practical ways:
For AvKARE eye drops, that means you do not have to reconstruct the recall from scattered screenshots or forum posts. You can start with the product record, confirm whether the bottle belongs in the affected product family, and then narrow to lot-level checking. That is a better workflow than web searching the phrase "are AvKARE eye drops safe" and hoping the top result is current.
This matters even more in homes where multiple people use eye products. One family member may have lubricant drops in a purse, another keeps a bottle by the bed, and someone else has a half-used carton in a travel bag. Centralized checking avoids the common mistake of verifying one bottle and assuming every similar bottle in the house is fine.
No. The public recall notice identifies specific ophthalmic products and affected lots, not every product AvKARE sells. The safe approach is to verify the exact item in your possession by product name, NDC, and lot number rather than assuming either total safety or total recall.
Only if you have verified that the exact product and lot are not part of the recall. An unopened bottle from a recalled lot should still not be used because the concern is product quality and sterility assurance, not whether the consumer already opened it.
Do not use it until you can identify it. Check the carton, side label, pharmacy paperwork, or retailer packaging. If the lot remains unreadable, replacement is the safer choice than continued use because you cannot reliably clear it against the recall notice.
Yes. FDA has repeatedly warned that contaminated ophthalmic products can cause serious eye infections, and in past events involving other brands the agency linked eye drops to hospitalization, permanent vision loss, and death. That is why sterility-related recalls should be treated as urgent product checks, not minor clerical issues.
Follow the recall notice and the seller's instructions. AvKARE's recall page tells customers to remove affected lots from active inventory and provides return steps for credit. If you already used the product and developed symptoms, keep the bottle and packaging long enough to document the details for your clinician and for any FDA MedWatch report.